Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-03-11 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于公司聘任副总裁的公告
Board/Management Information Classification · 100% confidence The document is a company announcement regarding the appointment of a new vice president (副总裁) at 贝达药业股份有限公司. It includes details about the appointment decision made by the board, the nominee's resume, and compliance statements about the nominee's qualifications and lack of conflicts of interest. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to shareholder votes or meetings. The document is clearly about management changes, specifically the hiring of a senior executive. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this appointment, confirming it is not a full report or announcement of a report publication.
2018-03-11 Chinese
关于控股子公司股份置换的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 贝达药业股份有限公司 regarding a share swap transaction between its wholly controlled subsidiaries. It details the transaction background, the necessity of merging two subsidiaries, company profiles, and the impact on the listed company. The document is a formal announcement of a corporate transaction involving share swaps within subsidiaries, not a full financial report, earnings release, or management discussion. It is not a regulatory certification or a report publication announcement. The content fits the category of Capital/Financing Update (CAP) as it relates to changes in capital structure through share swaps and internal acquisitions. The document length is 3157 characters, consistent with an announcement rather than a full report.
2018-03-11 Chinese
第二届董事会第十九次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 19th meeting of the 2nd Board of Directors of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and voting results on specific agenda items such as a share swap transaction between subsidiaries and the appointment of a new vice president. The document explicitly states it is a "董事会会议决议公告" (Board of Directors Meeting Resolution Announcement). There is no financial data, earnings information, or detailed management discussion. It is not a full report but an announcement of board decisions. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1597 characters), consistent with an announcement rather than a full report.
2018-03-11 Chinese
股东股份减持的进展公告
Major Shareholding Notification Classification · 95% confidence The document is a shareholder announcement regarding the progress of a shareholding reduction by a significant shareholder, BETA PHARMA, INC. It details the number of shares reduced, the method of reduction, the period, and compliance with relevant regulations. The document does not contain financial statements or performance data but focuses on the update of shareholding changes by a major shareholder. This fits the definition of a Major Shareholding Notification (MRQ). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS. Therefore, the correct classification is MRQ with high confidence.
2018-03-06 Chinese
股东股份质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a shareholder of the company. It details the number of shares pledged, the pledgee, the purpose, and cumulative pledge information. It does not contain financial statements, management discussion, or report content. It is a regulatory announcement about shareholder share pledging activity, which fits the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like Major Shareholding Notification (MRQ) because it is about pledged shares, not ownership threshold changes.
2018-03-05 Chinese
股东股份减持的进展公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the progress of shareholding reduction by major shareholders of the company. It details the number of shares reduced, the reduction methods, periods, prices, and the resulting shareholding percentages. It references compliance with regulations on shareholder share reduction and confirms that the reduction does not affect control or governance. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of changes in significant share ownership levels, fitting the definition of a Major Shareholding Notification.
2018-03-01 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.